Novartis downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser downgraded Novartis to Underweight with a price target of CHF 89. The analyst has concerns over the company’s pipeline and believes the shares are close to fair value.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.